What's Happening?
Boston Scientific Corporation has announced positive results from the FRACTURE Investigational Device Exemption (IDE) trial for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter. The trial, which enrolled 420 patients with severe coronary artery
disease (CAD), met its primary safety and effectiveness endpoints. The SEISMIQ 4CE catheter uses laser energy within a balloon catheter to generate acoustic pressure waves that fracture calcium in coronary arteries, facilitating stent delivery and expansion. The trial demonstrated a 93.3% rate of freedom from major adverse cardiac events (MACE) at 30 days and a 93.7% rate of procedural success. These results were presented at the EuroPCR 2026 congress, highlighting the catheter's potential to improve outcomes for high-risk patients with severe coronary calcification.
Why It's Important?
The successful trial of the SEISMIQ 4CE catheter represents a significant advancement in the treatment of coronary artery disease, a condition affecting a substantial portion of the population undergoing percutaneous coronary intervention (PCI). The catheter's ability to effectively manage severe coronary calcification could reduce procedural complications and improve patient outcomes. This development is crucial as it addresses a critical need in coronary care, potentially offering a new, differentiated option for physicians. The trial's success also supports Boston Scientific's regulatory submission for the device, which could lead to broader adoption and availability, ultimately benefiting patients and healthcare providers by enhancing treatment efficacy and safety.
What's Next?
Following the trial's success, Boston Scientific plans to continue monitoring the enrolled patients for two years post-procedure. The company is likely to pursue regulatory approval for the SEISMIQ 4CE catheter, which could lead to its introduction into the market. If approved, the device may become a standard tool in the treatment of severe coronary artery disease, potentially influencing clinical practices and guidelines. The ongoing evaluation and potential approval process will be closely watched by healthcare professionals and industry stakeholders, as the catheter's adoption could significantly impact the management of coronary calcification in PCI procedures.
